Financials data is unavailable for this security.
View more
Year on year Kissei Pharmaceutical Co Ltd grew revenues 11.98% from 67.49bn to 75.58bn while net income improved 6.01% from 10.53bn to 11.16bn.
| Gross margin | 49.88% |
|---|---|
| Net profit margin | 13.31% |
| Operating margin | 4.49% |
| Return on assets | 4.38% |
|---|---|
| Return on equity | 5.11% |
| Return on investment | 4.75% |
More ▼
Cash flow in JPYView more
In 2024, cash reserves at Kissei Pharmaceutical Co Ltd fell by 3.00bn. However, Cash Flow from Investing totalled 8.69bn, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 1.68bn for operations while cash used for financing totalled 10.01bn.
| Cash flow per share | 343.99 |
|---|---|
| Price/Cash flow per share | 11.91 |
| Book value per share | 4,969.03 |
|---|---|
| Tangible book value per share | 4,926.89 |
More ▼
Balance sheet in JPYView more
| Current ratio | 5.50 |
|---|---|
| Quick ratio | 4.15 |
| Total debt/total equity | 0.0057 |
|---|---|
| Total debt/total capital | 0.0057 |
More ▼
Growth rates in JPY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 2.50% and 8.01%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 2.32% |
|---|---|
| Div growth rate (5 year) | 10.40% |
| Payout ratio (TTM) | 35.42% |
| EPS growth(5 years) | 16.02 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -13.61 |
More ▼
